MedTrace Logo

Topical Tacrolimus in Vernal Keratoconjunctivitis

NCT02456025 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-11-24

No results posted yet for this study

Summary

The main aim of this study is to evaluate the efficacy and safety of topical tacrolimus 0.01% eyedrops in patients with vernal keratoconjunctivitis.

Conditions

  • Vernal Keratoconjunctivitis

Interventions

DRUG

Topical tacrolimus

Topical tacrolimus 0.01% twice daily for one month

Sponsors & Collaborators

  • The Eye Center and The Eye Foundation for Research in Ophthalmology

    lead OTHER

Principal Investigators

  • Samir S Shoughy · THE EYE CENTER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02456025 on ClinicalTrials.gov